From a technical perspective, Verve Therapeutics (VERV) is looking like an interesting pick, as it just reached a key level of support. VERV recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a ...

Verve Therapeutics (VERV) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Okay. Welcome everyone to twenty twenty five Jefferies Global Healthcare Conference. It it is my my name is Roger Song, one of the senior analysts covers MidCap biotech in US. And then it's my pleasure to have the next five star chat with our company, Zach, from the so excuse me. So from the Verve Therapeutics. So it it is a it is it is a very exciting timing for Verve because they just reported a very exciting data from the one tw ...

Investor Contact Jen Robinson Verve Therapeutics, Inc. jrobinson@vervetx.com Media Contact Ashlea Kosikowski 1AB ashlea@1abmedia.com Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NY Goldman Sachs 46 Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL Live webcasts will be available in the investor section of the company's website at www.vervetx.com. The webcasts will be archived for 30 days following the fireside chats. ...

Summary of Verve Therapeutics (VERV) 2025 Conference Call Company Overview - **Company**: Verve Therapeutics - **Industry**: Biotechnology, specifically focusing on gene editing therapies for cholesterol reduction Key Points and Arguments Progress and Pipeline - Verve is developing one-time therapies aimed at lifelong cholesterol reduction through IV infusion targeting the PCSK9 gene [3][4] - Initial Phase 1 data shows well-tolerated safety and significant efficacy with LDL reductions of 50-60%, with one patient achieving a 69% reduction [4] - The company is also working on additional programs targeting ANGPTL3 and LPA, with updates expected in the second half of the year [5][6] Regulatory Environment - The new leadership at the FDA, particularly Dr. Prasad, is seen as an opportunity for Verve, aligning with their focus on meaningful clinical endpoints like LDL levels [10][11] - Verve's PCSK9 therapy is positioned to provide substantial value, potentially reducing coronary disease risk by 80-90% [12] Clinical Development - Transition from first-generation (Vrb 101) to second-generation (Vrb 102) therapies has improved safety profiles due to advancements in lipid nanoparticle delivery systems [15][16] - Ongoing dose escalation studies are expected to yield further efficacy data, with hopes of achieving higher LDL reduction percentages [19] Partnership with Eli Lilly - Verve has a partnership with Eli Lilly, which includes an opt-in decision expected in the second half of the year, where Lilly would cover a third of worldwide development costs and 50% of US commercialization expenses [21][22] - The partnership is focused on a multimodal pipeline for cardiovascular disease targets, including LPA and ANGPTL3 [23] Market Landscape and Competition - Despite the presence of oral medications for cholesterol reduction, Verve's one-time therapy addresses a significant unmet need, as many patients do not achieve treatment goals with existing options [29][30] - Patient and physician preferences indicate a strong demand for one-time therapies over daily pills [30][31] ANGPTL3 Target - The ANGPTL3 target is supported by strong genetic evidence and pharmacologic validation, with the potential to lower both LDL cholesterol and triglycerides [34] - Previous safety concerns with other ANGPTL3 therapies are attributed to specific drug-related issues rather than the target itself [36] Future Directions - Verve is optimistic about the upcoming data updates for both PCSK9 and ANGPTL3 programs, with plans to leverage learnings from previous studies to enhance study designs [40] - The company is also exploring monetization opportunities for its proprietary GalNAc LNP delivery technology, which has shown promising safety profiles [49][51] Competitive Landscape - The emergence of competitors like CRISPR in the gene editing space is acknowledged, with Verve focusing on differentiating its approach through established safety and efficacy data [38][53] Additional Important Insights - The ongoing trials and partnerships are critical for Verve's strategy to establish itself in the competitive landscape of cholesterol-lowering therapies [47][48] - The company remains confident in the potential of its therapies to address significant cardiovascular health challenges, particularly in light of the limitations of current treatment options [45][46]

Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50.70%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-48001 ...

Exhibit 99.1 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress ...

Company Overview - Verve Therapeutics is a clinical-stage biotech company focused on developing gene editing therapies, particularly VERVE-102, aimed at treating heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease [2][4] - The company has a partnership with Eli Lilly, which provides financial backing and reduces the risk of funding issues [5] Clinical Progress - Verve Therapeutics recently announced positive results from a Phase 1b clinical trial for VERVE-102, showing a mean LDL-C reduction of 53% in patients after a single injection [3][4] - The potential target market for VERVE-102 includes approximately three million patients in the U.S. and the European Union, and 31 million globally [3] Market Expectations - Wall Street has set an average price target of $24.43 for Verve Therapeutics, suggesting a potential stock increase of 321% over the next 12 months [1] - Despite the promising clinical results, the stock only saw a 24% increase in one day following the announcement, indicating cautious market sentiment [4] Future Outlook - The company plans to start Phase 2 studies in the second half of the year, but it may take a couple of years before VERVE-102 enters Phase 3 studies [5][6] - There are concerns about potential clinical and regulatory setbacks that could impact the company's progress and stock performance [4][6]

Core Viewpoint - Verve Therapeutics experienced a significant stock price increase of 40% due to positive laboratory news and favorable analyst reports [1]. Company Developments - Verve is a clinical-stage biotech company focused on its drug pipeline, with recent encouraging results from a phase 1b clinical trial of VERVE-102, aimed at treating heterozygous familial hypercholesterolemia (HeFH) [2]. - The trial involved 14 patients and demonstrated efficacy in reducing low-density lipoprotein cholesterol (LDL-C) levels, with no serious adverse events reported, indicating a well-tolerated treatment [3]. Analyst Reactions - Following the trial results, analysts issued bullish notes on Verve, with several raising their price targets; Cantor Fitzgerald upgraded its recommendation to a buy [3]. - Despite the overall positive sentiment, JPMorgan Chase analyst Eric Joseph lowered his price target from $19 to $16 per share [4]. - BMO Capital's Kostas Biliouris reiterated an outperform (buy) recommendation, noting that the drug's performance exceeded expectations and its safety profile suggested a wide therapeutic window [4].

Shares of Verve Therapeutics (VERV) surged 26.4% on Monday and continue to soar today after the company announced positive initial data from an early-stage study of its investigational candidate, VERVE-102, which is being developed for reducing cholesterol levels. VERVE-102 is a novel, in vivo, investigational base editing medicine.The patient population enrolled in the phase Ib Heart-2 study comprises individuals with heterozygous familial hypercholesterolemia and/or premature coronary artery disease — two ...